Question 1

What is Survodutide?

Accepted Answer

Survodutide is a 29-amino-acid peptide developed by Boehringer Ingelheim with Zealand Pharma. Its research code is BI 456906. It acts on both the GLP-1 receptor and the glucagon receptor, which is why it is called a dual agonist.

Question 2

Is Survodutide FDA-approved?

Accepted Answer

No. As of June 2026, survodutide is investigational and is not FDA-approved for any human use. The Phase 3 SYNCHRONIZE-1 trial reported positive topline results on April 28, 2026, and full data is due at the ADA 2026 Scientific Sessions in June.

Question 3

How much weight did people lose with Survodutide?

Accepted Answer

In the Phase 3 SYNCHRONIZE-1 trial, adults with obesity or overweight without type 2 diabetes lost an average of 16.6% of body weight at 76 weeks, versus 3.2% on placebo. 85.1% of survodutide participants reached at least a 5% weight loss versus 38.8% on placebo.

Question 4

How is Survodutide dosed in clinical trials?

Accepted Answer

The Phase 2 obesity trial used once-weekly subcutaneous arms of 0.6 mg, 2.4 mg, 3.6 mg, or 4.8 mg, with a 20-week dose escalation followed by 26 weeks of maintenance. Phase 3 SYNCHRONIZE-1 used an extended, more flexible escalation. This is trial-protocol reporting, not a dosing recommendation.

Question 5

Can I buy Survodutide?

Accepted Answer

Survodutide is not available by prescription in the United States as of June 2026. Some research suppliers sell it under research-use-only labels, but those products are not regulated as prescription drugs and are not intended for human use. Always confirm current FDA status before drawing conclusions.

Question 6

How does Survodutide compare to Retatrutide?

Accepted Answer

Both are investigational once-weekly subcutaneous peptides. Survodutide targets GLP-1 and glucagon. Retatrutide targets GLP-1, GIP, and glucagon. In headline trials, retatrutide reported higher top-arm weight loss than Survodutide, but the two have not been compared head-to-head.

Question 7

How does Survodutide compare to Tirzepatide?

Accepted Answer

Tirzepatide is GLP-1 plus GIP. Survodutide is GLP-1 plus glucagon. Tirzepatide is FDA-approved for type 2 diabetes (Mounjaro) and for obesity (Zepbound). Survodutide is still investigational. No head-to-head trial has been published.

Question 8

What are the main Survodutide observed effects?

Accepted Answer

The most common Survodutide observed effects are nausea, vomiting, diarrhea, and constipation. In the Phase 2 obesity trial, around 75% of Survodutide participants reported a stomach or gut observed effect versus 42% on placebo. Most happened during the fast 20-week dose increase. Phase 3 SYNCHRONIZE-1 reported mostly mild to moderate stomach and gut observed effects with a slower dose increase.

Question 9

Who should avoid Survodutide?

Accepted Answer

Groups that should avoid Survodutide outside a clinical trial include pregnant or breastfeeding people, people with a personal or family history of medullary thyroid cancer or MEN 2, people with pancreatitis history, people with severe stomach or gut disease, children and teenagers, and anyone with known peptide allergies.

Question 10

How is Survodutide reconstituted?

Accepted Answer

For research-use vials, a common approach is to add 1.0 to 2.0 mL of bacteriostatic water per vial. A 6 mg vial with 1.0 mL of BAC water gives 6.0 mg/mL; a 10 mg vial with 1.0 mL gives 10.0 mg/mL. On a U-100 insulin syringe, 1 unit equals 0.01 mL. Swirl gently, do not shake, and refrigerate after mixing.

Question 11

What is the LIVERAGE program?

Accepted Answer

LIVERAGE and LIVERAGE-Cirrhosis are Phase 3 Survodutide trials for MASH, a serious fatty liver disease. They include adults with moderate to advanced liver scarring, including cirrhosis. Results are expected later in 2026.

Question 12

Is this page medical advice?

Accepted Answer

No. This page is an educational research-context reference. Survodutide is not FDA-approved and is not available by prescription. Talk to a qualified clinician before considering any peptide.

Phase	Reference amount	Units / volume
Weeks 1–2	0.6 mg	600 mcg
Weeks 3–4	1.2 mg	1200 mcg
Weeks 5–6	1.8 mg	1800 mcg
Weeks 7–8	2.4 mg	2400 mcg
Weeks 9–10	3.6 mg	3600 mcg
Weeks 11–12	4.8 mg	4800 mcg
Week 13+	6.0 mg	6000 mcg

Survodutide.

Calculated volume reference

Cited protocol & reconstitution guide